Joseph Brady joined Flagship Pioneering as an associate in 2020 after completing the firm’s Fellowship Program. At Flagship Joe works as part of a team of entrepreneurial scientists to drive ventures from origination to value. In this role, he imagines, creates, and advances the next generation of Flagship’s first-in-category product platforms in the life sciences.
A chemical engineer by training, Joe completed his doctorate in the lab of J. Christopher Love at MIT. His research focused on leveraging a multi-omics approach to diagnose and improve productivity of therapeutic proteins and subunit vaccines in an alternative expression system. He also supported early go-to-market efforts, and served as an independent consultant for a disruptive biomanufacturing start-up launched from the lab in 2019.
Joe pioneered the application of multi-omics (WGS, RNAseq, ATACseq, Riboseq) to alleviate bottlenecks in protein expression and biomanufacturing, and his work resulted in multiple publications, including in Nature Biotechnology and ACS Synthetic Biology. He engaged in high-impact collaborations with the Bill & Melinda Gates Foundation and the AltHost Consortium with leading pharmaceutical companies.
Prior to graduate school, Joe worked in biopharma R&D, first at GlaxoSmithKline and later at Janssen Pharmaceuticals. Joe holds a Ph.D. in Chemical Engineering from MIT and a B.S. in Chemical Engineering from Villanova University.